Page 45 - investor presentation

Advisory Board Singapore FMC SK Core Investment Team

Donghoon Lee Sungmin Woo
Advanced Healthcare - Bio/CMO
Materials Healthcare - SE Asia
Head of Global Bio/CMO Investment Group Head of Healthcare Investment in SE Asia

Education Education
M.B.A from Ohio State Univ. FisherCollege B.S. in Information and Industrial
of Business Engineering, Yonsei Univ.
Green B.B.A., Seoul National Univ.
Tech

SUMMARY SUMMARY
Mr. Lee has more than 20 years of business development and investment experi- Mr. Woo joined SK in 2015 and led SK Group’s global healthcare investment and
ICT/ ences in bio pharmaceutical sector, and he is currently responsible for SK’s bio/CMO operation, including pharmaceutical/CMO business, hospital and emerging health-
Digital business, including SK pharmteco, hea quartered in the US, and global manufactur- care business in US, SEA, Korea and China.
ing pre ence in the US. Europe and Korea and 4 R&D centers
Currently, he is responsible for healthcare chain investment in SE Asia at SK SUPEX
Since he joined SK, he led the major global bio investments such as Roivant and the Council, SK’s control tower for global investment, looking after Vietnam, Malaysia,
following JV (ProteoVant), French CDMO company Yposkesi, and leading CGT (Cell Indonesia and Singapore across pharmaceutical, drug distribution and retail, hospi-
and Gene Therapy) company GenEdit. tals and clinics chains, and digital platform for remote diagnosis.

Prior to joining SK, Mr. Lee was a CEO of Dona Socio Holdings (Korean pharmaceutical Prior to joining SK, Mr. Woo spent more than 15 years in strategy consulting (Oliver
Health- company) and Head of Global Business Develo ment at Donga ST. He also worked for Wyman and Booz Allen Hamilton) and investment banking (Macquarie Securities)
care KPMG as a Head of Financial Advisory Services in Korea for M&A and transactional based in Seoul, Korea, and he also worked as a computer programmer at Yahoo!
advisory. based in San Jose, US.

45
45
44
44 45
44